BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37611378)

  • 1. Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
    Nasioudis D; Latif NA; Ko EM; Cory L; Kim SH; Martin L; Simpkins F; Giuntoli R
    Gynecol Oncol; 2023 Oct; 177():14-19. PubMed ID: 37611378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
    Boscolo Bielo L; Repetto M; Crimini E; Belli C; Setola E; Parma G; Fusco N; Barberis M; Guerini Rocco E; Marra A; Colombo N; Curigliano G
    Oncologist; 2024 May; ():. PubMed ID: 38716772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.
    Heeke AL; Pishvaian MJ; Lynce F; Xiu J; Brody JR; Chen WJ; Baker TM; Marshall JL; Isaacs C
    JCO Precis Oncol; 2018; 2018():. PubMed ID: 30234181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes.
    Emelyanova M; Pudova E; Khomich D; Krasnov G; Popova A; Abramov I; Mikhailovich V; Filipenko M; Menshikova S; Tjulandin S; Pokataev I
    Ther Adv Med Oncol; 2022; 14():17588359221083050. PubMed ID: 35309086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of lymphadenectomy for apparent early stage uterine sarcoma; a comprehensive analysis of the National Cancer Database.
    Nasioudis D; Mastroyannis SA; Latif NA; Ko EM; Haggerty AF; Kim SH; Morgan MA; Giuntoli RL
    Surg Oncol; 2021 Sep; 38():101589. PubMed ID: 33957499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
    Westphalen CB; Fine AD; André F; Ganesan S; Heinemann V; Rouleau E; Turnbull C; Garcia Palacios L; Lopez JA; Sokol ES; Mateo J
    Clin Cancer Res; 2022 Apr; 28(7):1412-1421. PubMed ID: 34740923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
    Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
    Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
    Heeke AL; Xiu J; Elliott A; Korn WM; Lynce F; Pohlmann PR; Isaacs C; Swain SM; Vidal G; Schwartzberg LS; Tan AR
    Breast Cancer Res Treat; 2020 Nov; 184(2):265-275. PubMed ID: 32776290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
    Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
    Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.
    Pishvaian MJ; Blais EM; Brody JR; Rahib L; Lyons E; De Arbeloa P; Hendifar A; Mikhail S; Chung V; Sohal DPS; Leslie S; Mason K; Tibbets L; Madhavan S; Matrisian LM; Petricoin E
    JCO Precis Oncol; 2019 Dec; 3():1-10. PubMed ID: 35100730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.
    Hensley ML; Chavan SS; Solit DB; Murali R; Soslow R; Chiang S; Jungbluth AA; Bandlamudi C; Srinivasan P; Tap WD; Rosenbaum E; Taylor BS; Donoghue MTA; Hyman DM
    Clin Cancer Res; 2020 Jul; 26(14):3881-3888. PubMed ID: 32299819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma.
    Xie F; Ding D; Lin C; Cunningham D; Wright M; Javed AA; Azad N; Lee V; Donehower R; De Jesus-Acosta A; Le DT; Pishvaian M; Shin EJ; Lennon AM; Khashab M; Singh V; Klein AP; Roberts NJ; Hacker-Prietz A; McPhaul T; Burkhart RA; Burns WR; Narang A; Zaheer A; Fishman EK; Thompson ED; Anders R; Yu J; He J; Wolfgang CL; Zheng L; Liu D; Wu K; Laheru DA
    JCO Precis Oncol; 2022 Jun; 6():e2100404. PubMed ID: 35737913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study.
    Le Page C; Almadani N; Turashvili G; Bataillon G; Portelance L; Provencher D; Mes-Masson AM; Gilks B; Hoang L; Rahimi K
    Int J Gynecol Pathol; 2021 Sep; 40(5):487-494. PubMed ID: 33720083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
    Marks EI; Matera R; Olszewski AJ; Yakirevich E; El-Deiry WS; Safran H; Carneiro BA
    Am J Clin Oncol; 2021 Feb; 44(2):68-73. PubMed ID: 33298767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staging of uterine sarcomas.
    Tse KY; Crawford R; Ngan HY
    Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):733-49. PubMed ID: 21752716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in patients with uterine sarcoma: the SARCUT study.
    Zapardiel I; Gracia Segovia M; Macuks R; Mancari R; Achimas-Cadariu P; Corrado G; Bartusevicius A; Sukhin V; Muruzabal JC; Coronado Martín PJ; Gardella B; Piek JM; Concin N; Arab C; Papatheodorou D; Polterauer S; Iacoponi S; Nieto T; Lopez-Sanclemente MC; Trukhan H; Gil MM; Bakinovskaya I; Dalamanava A; Cucurull M; Rovski D; Baquedano L; Chiva L; Mardas M; Mavrichev SA; Klat J; Lopez de la Manzanara CA; Yildirim Y;
    Int J Gynecol Cancer; 2023 Jun; 33(6):897-904. PubMed ID: 37192761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma.
    Nasioudis D; Chapman-Davis E; Frey M; Holcomb K
    J Gynecol Oncol; 2017 Jul; 28(4):e46. PubMed ID: 28541635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Therapeutics in the Treatment of Uterine Sarcoma.
    Bose S; Schwartz GK; Ingham M
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():900-909. PubMed ID: 35714303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.